Contraceptive Drugs And Devices Market Size, Share & Trends Analysis Report By Product (Contraceptive Drugs (Contraceptive Pills, Patch, Injectable), Contraceptive Devices), By Region, And Segment Forecasts, 2024 - 2030
This report can be delivered to the clients within 3 Business Days
Continuous Passive Motion Devices Market Growth & Trends
The global continuous passive motion devices market size is expected to reach USD 1.2 billion by 2030, registering a CAGR of 5.2% from 2024 to 2030, according to a new report by Grand View Research, Inc. The increasing number of government initiatives along with the increasing number of ageing population are expected to drive the market growth over the forecast period.
CPM is initiated in the recovery room immediately post surgery procedure or during the early postoperative period. The therapy time may range from 1 to 24 hours of treatment per day and is used as an adjunct to physical therapy that may continue for 1 to 6 weeks depending on the degree of rehabilitation required. In February 2016, BTL launched BTL-CP Motion with 13 automatic preset protocols and 50 user defined protocols that improves movement for better therapy outcomes.
Factors such as the rising prevalence of disorders linked with trauma, joint replacement, or ligament reconstruction boost the CPM devices market. Osteoporosis decreases bone density, causing fracture even after a minor trauma incidence. The condition affects around 8.9 million population annually. The growing concern associated with population suffering from poor bone health has resulted in the development of efficient outpatient rehabilitation systems. Moreover, the improvement in reimbursement scenario, and the preference for minimal invasion offered by CPM devices as compared to surgical procedures are expected to boost the market growth.
Continuous Passive Motion Devices Market Report Highlights
Continuous Passive Motion Devices Market Growth & Trends
The global continuous passive motion devices market size is expected to reach USD 1.2 billion by 2030, registering a CAGR of 5.2% from 2024 to 2030, according to a new report by Grand View Research, Inc. The increasing number of government initiatives along with the increasing number of ageing population are expected to drive the market growth over the forecast period.
CPM is initiated in the recovery room immediately post surgery procedure or during the early postoperative period. The therapy time may range from 1 to 24 hours of treatment per day and is used as an adjunct to physical therapy that may continue for 1 to 6 weeks depending on the degree of rehabilitation required. In February 2016, BTL launched BTL-CP Motion with 13 automatic preset protocols and 50 user defined protocols that improves movement for better therapy outcomes.
Factors such as the rising prevalence of disorders linked with trauma, joint replacement, or ligament reconstruction boost the CPM devices market. Osteoporosis decreases bone density, causing fracture even after a minor trauma incidence. The condition affects around 8.9 million population annually. The growing concern associated with population suffering from poor bone health has resulted in the development of efficient outpatient rehabilitation systems. Moreover, the improvement in reimbursement scenario, and the preference for minimal invasion offered by CPM devices as compared to surgical procedures are expected to boost the market growth.
Continuous Passive Motion Devices Market Report Highlights
- Knee joint CPM devices have secured the dominant market share with 41.3% in 2023 owing to their widespread adoption after knee arthroplasty, ACL reconstruction, and other knee surgeries for outpatient knee rehabilitation.
- The growth of knee joints CPM devices is attributed to factors such as the increasing number of knee arthroplasty. The rise in road traffic accidents increases the number of orthopedic surgeries performed worldwide. Improvement of care in such cases involves ensuring better quality of post-hospital care, such as through CPM training program.
- Based on design, the market is segmented into fixed and portable devices wherein fixed devices dominated the market while portable CPM devices is anticipated to grow at the fastest rate owing to the increasing use of devices in home setting.
- On the basis of demographics, the market is segmented into adults (18 and above) and children (below 18) wherein adult population dominated the segment market owing to increasing number of ageing population with joint disorder.
- North America dominated the continuous passive motion devices market in 2023 in terms of revenue share owing to the rising government initiative to increase patient access to outpatient rehabilitation.
CHAPTER 1. METHODOLOGY AND SCOPE
1.1. Market Segmentation and Scope
1.2. Market Definitions
1.3. Research Methodology
1.3.1. Information Procurement
1.3.2. Information or Data Analysis
1.3.3. Market Formulation & Data Visualization
1.3.4. Data Validation & Publishing
1.4. Research Scope and Assumptions
1.4.1. List of Data Sources
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
CHAPTER 3. CONTRACEPTIVE DRUGS AND DEVICES MARKET VARIABLES, TRENDS, & SCOPE
3.1. Market Introduction/Lineage Outlook
3.2. Market Size and Growth Prospects (USD Million)
3.3. Market Dynamics
3.3.1. Market Drivers Analysis
3.3.2. Market Restraints Analysis
3.4. Contraceptive Drugs and Devices Market Analysis Tools
3.4.1. Porter’s Analysis
3.4.1.1. Bargaining power of the suppliers
3.4.1.2. Bargaining power of the buyers
3.4.1.3. Threats of substitution
3.4.1.4. Threats from new entrants
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Economic and Social landscape
3.4.2.3. Technological landscape
3.4.2.4. Environmental landscape
3.4.2.5. Legal landscape
CHAPTER 4. CONTRACEPTIVE DRUGS AND DEVICES MARKET: PRODUCT ESTIMATES & TREND ANALYSIS
4.1. Segment Dashboard
4.2. Contraceptive Drugs and Devices Market: Product Movement Analysis, 2023 & 2030 (USD Million)
4.3. Contraceptive Drugs
4.3.1. Contraceptive Drugs Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.3.2. Contraceptive Pills
4.3.2.1. Contraceptive Pills Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.3.3. Patch
4.3.3.1. Patch Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.3.4. Injectable
4.3.4.1. Injectable Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4. Contraceptive Devices
4.4.1. Contraceptive Devices Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4.2. Condom
4.4.2.1. Condom Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4.2.2. Male Condom
4.4.2.2.1. Male Condom Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4.2.3. Female Condom
4.4.2.3.1. Female Condom Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4.3. Subdermal Implants
4.4.3.1. Subdermal Implants Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4.4. Intrauterine Devices (IUDs)
4.4.4.1. Intrauterine Devices (IUDs) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4.4.2. Copper IUDs
4.4.4.2.1. Copper IUDs Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4.4.3. Hormonal IUDs
4.4.4.3.1. Hormonal IUDs Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4.5. Vaginal Ring
4.4.5.1. Vaginal Ring Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4.6. Diaphragm
4.4.6.1. Diaphragm Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 5. CONTRACEPTIVE DRUGS AND DEVICES MARKET: REGIONAL ESTIMATES & TREND ANALYSIS
5.1. Contraceptive Drugs and Devices Market Share, By Region, 2023 & 2030 (USD Billion)
5.2. North America
5.2.1. North America Contraceptive Drugs and Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.2.2. U.S.
5.2.2.1. U.S. Contraceptive Drugs and Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.2.3. Canada
5.2.3.1. Canada Contraceptive Drugs and Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.2.4. Mexico
5.2.4.1. Mexico Contraceptive Drugs and Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.3. Europe
5.3.1. Europe Contraceptive Drugs and Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.3.2. UK
5.3.2.1. UK Contraceptive Drugs and Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.3.3. Germany
5.3.3.1. Germany Contraceptive Drugs and Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.3.4. France
5.3.4.1. France Contraceptive Drugs and Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.3.5. Italy
5.3.5.1. Italy Contraceptive Drugs and Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.3.6. Spain
5.3.6.1. Spain Contraceptive Drugs and Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.3.7. Denmark
5.3.7.1. Denmark Contraceptive Drugs and Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.3.8. Sweden
5.3.8.1. Sweden Contraceptive Drugs and Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.3.9. Norway
5.3.9.1. Norway Contraceptive Drugs and Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.4. Asia Pacific
5.4.1. Asia Pacific Contraceptive Drugs and Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.4.2. Japan
5.4.2.1. Japan Contraceptive Drugs and Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.4.3. China
5.4.3.1. China Contraceptive Drugs and Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.4.4. India
5.4.4.1. India Contraceptive Drugs and Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.4.5. Australia
5.4.5.1. Australia Contraceptive Drugs and Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.4.6. South Korea
5.4.6.1. South Korea Contraceptive Drugs and Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.4.7. Thailand
5.4.7.1. Thailand Contraceptive Drugs and Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.5. Latin America
5.5.1. Latin America Contraceptive Drugs and Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.5.2. Brazil
5.5.2.1. Brazil Contraceptive Drugs and Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.5.3. Argentina
5.5.3.1. Argentina Contraceptive Drugs and Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.6. Middle East and Africa
5.6.1. Middle East and Africa Contraceptive Drugs and Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.6.2. South Africa
5.6.2.1. South Africa Contraceptive Drugs and Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.6.3. Saudi Arabia
5.6.3.1. Saudi Arabia Contraceptive Drugs and Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.6.4. UAE
5.6.4.1. UAE Contraceptive Drugs and Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.6.5. Kuwait
5.6.5.1. Kuwait Contraceptive Drugs and Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 6. COMPETITIVE LANDSCAPE
6.1. Recent Developments & Impact Analysis by Key Market Participants
6.2. Company Categorization
6.3. Company Heat Map Analysis
6.4. Company Profiles
6.4.1. Abbvie, Inc.
6.4.1.1. Participant’s Overview
6.4.1.2. Financial Performance
6.4.1.3. Product Benchmarking
6.4.1.4. Recent Developments/ Strategic Initiatives
6.4.2. Afaxys, Inc.
6.4.2.1. Participant’s Overview
6.4.2.2. Financial Performance
6.4.2.3. Product Benchmarking
6.4.2.4. Recent Developments/ Strategic Initiatives
6.4.3. Agile Therapeutics
6.4.3.1. Participant’s Overview
6.4.3.2. Financial Performance
6.4.3.3. Product Benchmarking
6.4.3.4. Recent Developments/ Strategic Initiatives
6.4.4. Bayer AG
6.4.4.1. Participant’s Overview
6.4.4.2. Financial Performance
6.4.4.3. Product Benchmarking
6.4.4.4. Recent Developments/ Strategic Initiatives
6.4.5. China Resources (Holdings) Co., Ltd.
6.4.5.1. Participant’s Overview
6.4.5.2. Financial Performance
6.4.5.3. Product Benchmarking
6.4.5.4. Recent Developments/ Strategic Initiatives
6.4.6. Church & Dwight Co., Inc.
6.4.6.1. Participant’s Overview
6.4.6.2. Financial Performance
6.4.6.3. Product Benchmarking
6.4.6.4. Recent Developments/ Strategic Initiatives
6.4.7. Cupid Limited
6.4.7.1. Participant’s Overview
6.4.7.2. Financial Performance
6.4.7.3. Product Benchmarking
6.4.7.4. Recent Developments/ Strategic Initiatives
6.4.8. Helm AG
6.4.8.1. Participant’s Overview
6.4.8.2. Financial Performance
6.4.8.3. Product Benchmarking
6.4.8.4. Recent Developments/ Strategic Initiatives
6.4.9. Johnson & Johnson Services, Inc.
6.4.9.1. Participant’s Overview
6.4.9.2. Financial Performance
6.4.9.3. Product Benchmarking
6.4.9.4. Recent Developments/ Strategic Initiatives
6.4.10. Organon Group of Companies
6.4.10.1. Participant’s Overview
6.4.10.2. Financial Performance
6.4.10.3. Product Benchmarking
6.4.10.4. Recent Developments/ Strategic Initiatives
6.4.11. Pfizer Inc.
6.4.11.1. Participant’s Overview
6.4.11.2. Financial Performance
6.4.11.3. Product Benchmarking
6.4.11.4. Recent Developments/ Strategic Initiatives
6.4.12. Veru, Inc.
6.4.12.1. Participant’s Overview
6.4.12.2. Financial Performance
6.4.12.3. Product Benchmarking
6.4.12.4. Recent Developments/ Strategic Initiatives
6.4.13. Viatris Inc.
6.4.13.1. Participant’s Overview
6.4.13.2. Financial Performance
6.4.13.3. Product Benchmarking
6.4.13.4. Recent Developments/ Strategic Initiatives
1.1. Market Segmentation and Scope
1.2. Market Definitions
1.3. Research Methodology
1.3.1. Information Procurement
1.3.2. Information or Data Analysis
1.3.3. Market Formulation & Data Visualization
1.3.4. Data Validation & Publishing
1.4. Research Scope and Assumptions
1.4.1. List of Data Sources
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
CHAPTER 3. CONTRACEPTIVE DRUGS AND DEVICES MARKET VARIABLES, TRENDS, & SCOPE
3.1. Market Introduction/Lineage Outlook
3.2. Market Size and Growth Prospects (USD Million)
3.3. Market Dynamics
3.3.1. Market Drivers Analysis
3.3.2. Market Restraints Analysis
3.4. Contraceptive Drugs and Devices Market Analysis Tools
3.4.1. Porter’s Analysis
3.4.1.1. Bargaining power of the suppliers
3.4.1.2. Bargaining power of the buyers
3.4.1.3. Threats of substitution
3.4.1.4. Threats from new entrants
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Economic and Social landscape
3.4.2.3. Technological landscape
3.4.2.4. Environmental landscape
3.4.2.5. Legal landscape
CHAPTER 4. CONTRACEPTIVE DRUGS AND DEVICES MARKET: PRODUCT ESTIMATES & TREND ANALYSIS
4.1. Segment Dashboard
4.2. Contraceptive Drugs and Devices Market: Product Movement Analysis, 2023 & 2030 (USD Million)
4.3. Contraceptive Drugs
4.3.1. Contraceptive Drugs Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.3.2. Contraceptive Pills
4.3.2.1. Contraceptive Pills Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.3.3. Patch
4.3.3.1. Patch Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.3.4. Injectable
4.3.4.1. Injectable Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4. Contraceptive Devices
4.4.1. Contraceptive Devices Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4.2. Condom
4.4.2.1. Condom Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4.2.2. Male Condom
4.4.2.2.1. Male Condom Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4.2.3. Female Condom
4.4.2.3.1. Female Condom Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4.3. Subdermal Implants
4.4.3.1. Subdermal Implants Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4.4. Intrauterine Devices (IUDs)
4.4.4.1. Intrauterine Devices (IUDs) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4.4.2. Copper IUDs
4.4.4.2.1. Copper IUDs Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4.4.3. Hormonal IUDs
4.4.4.3.1. Hormonal IUDs Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4.5. Vaginal Ring
4.4.5.1. Vaginal Ring Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4.6. Diaphragm
4.4.6.1. Diaphragm Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 5. CONTRACEPTIVE DRUGS AND DEVICES MARKET: REGIONAL ESTIMATES & TREND ANALYSIS
5.1. Contraceptive Drugs and Devices Market Share, By Region, 2023 & 2030 (USD Billion)
5.2. North America
5.2.1. North America Contraceptive Drugs and Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.2.2. U.S.
5.2.2.1. U.S. Contraceptive Drugs and Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.2.3. Canada
5.2.3.1. Canada Contraceptive Drugs and Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.2.4. Mexico
5.2.4.1. Mexico Contraceptive Drugs and Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.3. Europe
5.3.1. Europe Contraceptive Drugs and Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.3.2. UK
5.3.2.1. UK Contraceptive Drugs and Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.3.3. Germany
5.3.3.1. Germany Contraceptive Drugs and Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.3.4. France
5.3.4.1. France Contraceptive Drugs and Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.3.5. Italy
5.3.5.1. Italy Contraceptive Drugs and Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.3.6. Spain
5.3.6.1. Spain Contraceptive Drugs and Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.3.7. Denmark
5.3.7.1. Denmark Contraceptive Drugs and Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.3.8. Sweden
5.3.8.1. Sweden Contraceptive Drugs and Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.3.9. Norway
5.3.9.1. Norway Contraceptive Drugs and Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.4. Asia Pacific
5.4.1. Asia Pacific Contraceptive Drugs and Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.4.2. Japan
5.4.2.1. Japan Contraceptive Drugs and Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.4.3. China
5.4.3.1. China Contraceptive Drugs and Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.4.4. India
5.4.4.1. India Contraceptive Drugs and Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.4.5. Australia
5.4.5.1. Australia Contraceptive Drugs and Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.4.6. South Korea
5.4.6.1. South Korea Contraceptive Drugs and Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.4.7. Thailand
5.4.7.1. Thailand Contraceptive Drugs and Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.5. Latin America
5.5.1. Latin America Contraceptive Drugs and Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.5.2. Brazil
5.5.2.1. Brazil Contraceptive Drugs and Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.5.3. Argentina
5.5.3.1. Argentina Contraceptive Drugs and Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.6. Middle East and Africa
5.6.1. Middle East and Africa Contraceptive Drugs and Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.6.2. South Africa
5.6.2.1. South Africa Contraceptive Drugs and Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.6.3. Saudi Arabia
5.6.3.1. Saudi Arabia Contraceptive Drugs and Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.6.4. UAE
5.6.4.1. UAE Contraceptive Drugs and Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.6.5. Kuwait
5.6.5.1. Kuwait Contraceptive Drugs and Devices Market Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 6. COMPETITIVE LANDSCAPE
6.1. Recent Developments & Impact Analysis by Key Market Participants
6.2. Company Categorization
6.3. Company Heat Map Analysis
6.4. Company Profiles
6.4.1. Abbvie, Inc.
6.4.1.1. Participant’s Overview
6.4.1.2. Financial Performance
6.4.1.3. Product Benchmarking
6.4.1.4. Recent Developments/ Strategic Initiatives
6.4.2. Afaxys, Inc.
6.4.2.1. Participant’s Overview
6.4.2.2. Financial Performance
6.4.2.3. Product Benchmarking
6.4.2.4. Recent Developments/ Strategic Initiatives
6.4.3. Agile Therapeutics
6.4.3.1. Participant’s Overview
6.4.3.2. Financial Performance
6.4.3.3. Product Benchmarking
6.4.3.4. Recent Developments/ Strategic Initiatives
6.4.4. Bayer AG
6.4.4.1. Participant’s Overview
6.4.4.2. Financial Performance
6.4.4.3. Product Benchmarking
6.4.4.4. Recent Developments/ Strategic Initiatives
6.4.5. China Resources (Holdings) Co., Ltd.
6.4.5.1. Participant’s Overview
6.4.5.2. Financial Performance
6.4.5.3. Product Benchmarking
6.4.5.4. Recent Developments/ Strategic Initiatives
6.4.6. Church & Dwight Co., Inc.
6.4.6.1. Participant’s Overview
6.4.6.2. Financial Performance
6.4.6.3. Product Benchmarking
6.4.6.4. Recent Developments/ Strategic Initiatives
6.4.7. Cupid Limited
6.4.7.1. Participant’s Overview
6.4.7.2. Financial Performance
6.4.7.3. Product Benchmarking
6.4.7.4. Recent Developments/ Strategic Initiatives
6.4.8. Helm AG
6.4.8.1. Participant’s Overview
6.4.8.2. Financial Performance
6.4.8.3. Product Benchmarking
6.4.8.4. Recent Developments/ Strategic Initiatives
6.4.9. Johnson & Johnson Services, Inc.
6.4.9.1. Participant’s Overview
6.4.9.2. Financial Performance
6.4.9.3. Product Benchmarking
6.4.9.4. Recent Developments/ Strategic Initiatives
6.4.10. Organon Group of Companies
6.4.10.1. Participant’s Overview
6.4.10.2. Financial Performance
6.4.10.3. Product Benchmarking
6.4.10.4. Recent Developments/ Strategic Initiatives
6.4.11. Pfizer Inc.
6.4.11.1. Participant’s Overview
6.4.11.2. Financial Performance
6.4.11.3. Product Benchmarking
6.4.11.4. Recent Developments/ Strategic Initiatives
6.4.12. Veru, Inc.
6.4.12.1. Participant’s Overview
6.4.12.2. Financial Performance
6.4.12.3. Product Benchmarking
6.4.12.4. Recent Developments/ Strategic Initiatives
6.4.13. Viatris Inc.
6.4.13.1. Participant’s Overview
6.4.13.2. Financial Performance
6.4.13.3. Product Benchmarking
6.4.13.4. Recent Developments/ Strategic Initiatives
